Table 3.
IgG antibodies seroprevalence against MCPyV VP1 S and VP2 F peptides in heathy subjects (HS).
| Age yrs | Number of samples | Number of positive samples (%) | |||
|---|---|---|---|---|---|
| Male | VP1 S | VP2 F | VP1 S+VP2 F | ||
| (%) | |||||
| 18-30 | 130 | 20.8 | 92 (70.8) | 90 (69.2) | 82 (63.1) |
| 31-40 | 120 | 36.7 | 79 (65.8) | 72 (60) | 68 (56.7) |
| 41-50 | 141 | 39 | 104 (73.8) | 102 (72.3) | 91 (64.5) |
| 51-65 | 157 | 53.5 | 122 (77.7) | 108 (68.8) | 104 (66.2) |
| Total | 548 | 38.3 | 397 (72.4) | 372 (67.8) | 345 (62.9) |
Serum samples (n=548) were from healthy subjects (HS). Statistical analyses were performed using the two-sided chi-square test. No statistical differences were detected among age-stratified groups (p>0.05).